



bis(hydroxyC<sub>1-6</sub>alkyl)amino, bis(C<sub>1-6</sub>alkoxyC<sub>1-6</sub>alkyl)amino, bis(aminoC<sub>1-6</sub>alkyl)amino, cyano, carboxyl, C<sub>1-6</sub>alkoxycarbonyl, aryloxy-carbonyl, phosphono, C<sub>1-6</sub>alkylphosphono, diC<sub>1-6</sub>alkylphosphono, sulfonic acid, and C<sub>1-6</sub>alkylsulfo; or R<sub>1</sub> and R<sub>2</sub>, together with the nitrogen atoms to which they are bound, form a saturated or unsaturated 5- to 7-membered heterocyclic ring containing one nitrogen atom and optionally further containing one or more heteroatoms selected from an oxygen atom, a nitrogen atom, and a sulfur atom; and


L is selected from the formula:





Claim 2. (Deleted).

3. (Previously Presented) The compound  the pharmaceutically acceptable salt thereof according to claim 1, wherein Z is a hydrogen atom, C<sub>1-6</sub>alkyl, C<sub>3-6</sub>cycloalkyl,

hydroxyC<sub>1-6</sub>alkyl, hydroxyC<sub>1-6</sub>alkoxyC<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxyC<sub>1-6</sub>alkyl,  
cyanoC<sub>1-6</sub>alkyl, pyridylC<sub>1-6</sub>alkyl, dihydroxyC<sub>1-6</sub>alkyl,  
trihydroxyC<sub>1-6</sub>alkyl, morpholinoC<sub>1-6</sub>alkyl,  
(N,N-diC<sub>1-6</sub>alkylamino)C<sub>1-6</sub>alkyl, or  
(N,N-bis(hydroxyC<sub>1-6</sub>alkyl)amino)C<sub>1-6</sub>alkyl.

4. (Previously Presented) The compound  for the 70 11/25/09  
pharmaceutically acceptable salt thereof according to claim 3,  
wherein Z is a hydrogen atom, methyl, ethyl, cyclopropyl,  
cyclopentyl, 2-hydroxyethyl, 2-(2-hydroxyethoxy)ethyl, 2-  
methoxyethyl, 2-cyanoethyl, 4-pyridylmethyl, 1-methoxybut-2-  
yl, 2,3-dihydroxyprop-1-yl, 1,3-dihydroxyprop-2-yl, 1,3-  
dihydroxy-2-hydroxymethylprop-2-yl, 2-morpholinoethyl, 1-  
hydroxyprop-2-yl, 1-hydroxy-3-methylbut-2-yl, 2-(N,N-  
dimethylamino)ethyl, 2-(N,N-bis(2-hydroxyethyl)amino)ethyl,  
2,4-dihydroxybutyl, 2,3,4-trihydroxybutyl, 2,3,4,5-  
tetrahydroxypentyl, or 2,3,4,5,6-pentahydroxyhexyl.

5. (Previously Presented) The compound  for the 70 11/25/09  
pharmaceutically acceptable salt thereof according to claim 1,  
wherein Y is a halogen atom, cyano, C<sub>1-6</sub>alkenyl, C<sub>2-6</sub>alkynyl,  
C<sub>1-6</sub>alkoxy,  
C<sub>1-6</sub>cycloalkylC<sub>1-6</sub>alkoxy, C<sub>2-6</sub>alkynyloxy, or haloC<sub>1-6</sub>alkoxy.

6. (Currently Amended) The compound  for the 70 11/25/09  
pharmaceutically acceptable salt thereof according to claim 5,

wherein Y is chloro, bromo, cyano, ethynyl, methoxy, trifluoromethoxy, cyclopropylmethoxy, 2-butyn-1-yloxy, or 2-chloroethoxy.

7. (Previously Presented) The compound <sup>76</sup> <sub>11/25/09</sub> for the pharmaceutically acceptable salt thereof according to claim 1, wherein

X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub>, X<sub>4</sub> and X<sub>5</sub> are each independently selected from a hydrogen atom, a halogen atom, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, haloC<sub>1-6</sub>alkyl, haloC<sub>1-6</sub>alkoxy, C<sub>1-6</sub>alkylthio, and haloC<sub>1-6</sub>alkylthio; or

X<sub>1</sub> and X<sub>2</sub>, X<sub>2</sub> and X<sub>3</sub>, X<sub>3</sub> and X<sub>4</sub>, and X<sub>4</sub> and X<sub>5</sub>, together with the carbon atoms to which they are bound, form a cyclohexane ring, a cyclopentane ring, a benzene ring, a pyridine ring, a pyrimidine ring, a 1,4-dioxane ring, a 1,3-dioxolane ring, a pyrrole ring, an imidazole ring, a thiazole ring, or a furan ring.

8. (Previously Presented) The compound or the pharmaceutically acceptable salt thereof according to claim 7, wherein

X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub>, X<sub>4</sub> and X<sub>5</sub> are each independently selected from a hydrogen atom, fluoro, chloro, bromo, methyl, ethyl, t-butyl, i-propyl, methoxy, i-propoxy, trifluoromethyl, trifluoromethoxy, methylthio, and trifluoromethylthio; or